Erratum: Rediscovering trazodone for the treatment of major depressive disorder (CNS Drugs (2012) 26 (1033-1049) DOI:10.1007/s40263-012-0010-5);Rediscovering trazodone for the treatment of major depressive disorder

CNS Drugs

Volumn 26, Issue 12, 2012, Pages 1033-1049

  Fagiolini, Andrea ^a   Comandini, Alessandro ^b   Dell'Osso, Mario Catena ^c   Kasper, Siegfried ^d  

^a UNIVERSITY OF SIENA   (Italy)

^b Piazzale della Stazione SNC   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CONTRAMID; DIAZEPAM; DOSULEPIN; FLUOXETINE; MIANSERIN; MIRTAZAPINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM;

AGITATION; ALZHEIMER DISEASE; ANTICHOLINERGIC EFFECT; ANTIDEPRESSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; BEDTIME DOSAGE; BULIMIA; COGNITIVE THERAPY; DEMENTIA; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FIBROMYALGIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PRIAPISM; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; XEROSTOMIA;

EID: 84873437001     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0088-4     Document Type: Erratum

References (107)

1. World Health Organization. Depression. http://www.who.int/mental-health/ management/depression/definition/en/ (2012). Accessed 13 May 2012.
2. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(Suppl E1):e08.
3. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet. 2007;370(9590):859-77.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association; 2010.
5. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67-104.
6. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.
7. Harter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int. 2010;107(40):700-8.
8. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults. http://www.nice.org.uk/ nicemedia/live/12329/45888/45888.pdf (2009). Accessed 14 Aug 2012.
9. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(Suppl 13):18-25.
10. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010;71(8):971-5.
11. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin. 2006;22(9):1825-37.
12. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
13. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-5.
14. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357-66.
15. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37-41.
16. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(Suppl 16):27-32.
17. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002;22(2):137-47.
18. Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry. 2000;61(Suppl 11):46-50.
19. Feighner JP, Boyer WF. Overview of USA controlled trials of trazodone in clinical depression. Psychopharmacology. 1988;95(Suppl):S50-3.
20. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-50.
21. Extended-release trazodone (Oleptro) for depression. Med Lett Drugs Ther. 2010;52(1351):91-2.
22. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14(10):536-46.
23. Brogden RN, Heel RC, Speight TM, Avery GS. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs. 1981;21(6):401-29.
24. 1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19(3):235-41.
25. Stahl SM. Stahl's essential psychopharmacology. 3rd ed. New York (NY): Cambridge University Press; 2008.
26. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28(2):402-12.
27. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53(3):83-5.
28. Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999;383(3):249-57.
29. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24(12):726-31.
30. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027-38.
31. Aziende Chimiche Riunite Angelini Francesco (ACRAF SpA). Trittico (trazodone hydrochloride) 75 mg and 150 mg prolonged-release tablets: summary of the product characteristics. http://www.angelini.it/public/schedepharma/ trittico-rilascio-prolung.htm. Accessed June 15 2012.
32. Medicines and Healthcare Products Regulatory Agency. Trazodone hydrochloride 50 mg and 100 mg capsules: summary of the product characteristics. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/ con2023774.pdf. Accessed 22 Aug 2012.
33. Oleptro™ (trazodone hydrochloride) extended-release tablets. P T 2011;36(2):2-18.
34. Rawls WN. Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). Drug Intell Clin Pharm. 1982;16(1):7-13.
35. Karhu D, Gossen ER, Mostert A, et al. Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects. Int J Clin Pharm Ther. 2011;49(12):730-43.
36. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444-7.
37. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry. 1991;52(7):294-9.
38. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol. 1994;14(2):99-106.
39. Kasper S, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin. 2005;21(8):1139-46.
40. Moon CA, Laws D, Stott PC, Hayes G. Efficacy and tolerability of controlled-release trazodone in depression: a large multicentre study in general practice. Curr Med Res Opin. 1990;12(3):160-8.
41. Munizza C, Olivieri L, Di Loreto G, Dionisio P. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2006;22(9):1703-13.
42. Sheehan DV, Croft HA, Gossen ER, et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry. 2009;6(5):20-33.
43. Sheehan DV, Rozova A, Gossen ER, Gibertini M. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull. 2009;42(4):5-22.
44. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995;10(1):3-9.
45. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol. 1994;14(3):170-9.
46. Blacker R, Shanks NJ, Chapman N, Davey A. The drug treatment of depression in general practice: a comparison of nocte administration of trazodone with mianserin, dothiepin and amitriptyline. Psychopharmacology. 1988;95(Suppl):S18-24.
47. Botros WA, Ankier SI, Priest RG, et al. Clinical assessment and performance tasks in depression: a comparison of amitriptyline and trazodone. Br J Psychiatry. 1989;155:479-82.
48. Davey A. A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology. 1988;95(Suppl):S25-30.
49. Debus JR, Rush AJ, Himmel C, et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988;49(11):422-6.
50. Moon CA, Davey A. The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology. 1988;95(Suppl):S7-13.
51. Altamura AC, Mauri MC, Rudas N, et al. Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: a controlled multicenter trial. Clin Neuropharmacol. 1989;12(Suppl 1):S25-33 (S4-7).
52. Ather SA, Ankier SI, Middleton RS. A double-blind evaluation of trazodone in the treatment of depression in the elderly. Br J Clin Pract. 1985;39(5):192-9.
53. Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41(6):216-20.
54. Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neurol. 1989;2(4):208-14.
55. Bayer AJ, Pathy MS, Cameron A, et al. A comparative study of conventional and controlled-release formulations of trazodone in elderly depressed patients. Clin Neuropharmacol. 1989;12(Suppl 1):S50-5 (discussion S6-7).
56. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders: American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37(11):1234-8.
57. Saccomani L, Rizzo P, Nobili L. Combined treatment with haloperidol and trazodone in patients with tic disorders. J Child Adolesc Psychopharmacol. 2000;10(4):307-10.
58. Catanese B, Dionisio A, Barillari G, De Martino C. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. Boll Chim Farm. 1978;117(7):424-7.
59. Detry O, Delwaide J, De Roover A, et al. Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report. Transplant Proc. 2009;41(8):3435-6.
60. Agnoli A, De Gregorio M, Dionisio A. Trazodone, a review of clinical literature and personal experience. Psychopathology. 1984;17(Suppl 2):88-103.
61. Haria M, Fitton A, McTavish D. Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging. 1994;4(4):331-55.
62. Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23(5):417-21.
63. Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharmacol Bull. 1984;20(2):272-9.
64. de Meester A, Carbutti G, Gabriel L, Jacques JM. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56(4):258-61.
65. Aronson MD, Hafez H. A case of trazodone-induced ventricular tachycardia. J Clin Psychiatry. 1986;47(7):388-9.
66. Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest. 1990;98(1):247-8.
67. Winkler D, Ortner R, Pjrek E, et al. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006;21(1):61-2.
68. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469-76.
69. Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 2005;510(1-2):75-85.
70. Jayaram G, Rao P. Safety of trazodone as a sleep agent for inpatients. Psychosomatics. 2005;46(4):367-9.
71. 2A antagonist trazodone. Clin Neuropharmacol. 2003;26(3):137-41.
72. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990;51(10):430-3.
73. Prapotnik M, Waschgler R, Konig P, et al. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharm Ther. 2004;42(2):120-4.
74. Bertschy G, Ragama-Pardos E, Muscionico M, et al. Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. Pharmacol Res. 2005;51(1):79-84.
75. Fabre LF Jr, Feighner JP. Long-term therapy for depression with trazodone. J Clin Psychiatry. 1983;44(1):17-21.
76. Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13(12):1707-17.
77. Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000;23(Suppl 1):S23-30 (discussion S6-8).
78. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):249-60.
79. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone. Neuropsychobiol. 2001;44(3):139-49.
80. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18(1):49-56.
81. Montgomery I, Oswald I, Morgan K, Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol. 1983;16(2):139-44.
82. Wheatley D. Trazodone: alternative dose regimens and sleep. Pharmatherapeutica. 1984;3(9):607-12.
83. Walsh JB, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191-8.
84. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069-72.
85. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51(Suppl):13-7.
86. Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(Suppl)17:28-31 (discussion 46-8).
87. Kallepalli BR, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adolesc Psychopharmacol. 1997;7(2):97-107.
88. Haffmans PM, Vos MS. The effects of trazodone on sleep disturbances induced by brofaromine. Eur Psychiatry. 1999;14(3):167-71.
89. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology. 1999;144(3):220-33.
90. Rush CR, Madakasira S, Hayes CA, et al. Trazodone and triazolam: acute subject-rated and performance-impairing effects in healthy volunteers. Psychopharmacology. 1997;131(1):9-18.
91. Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health. 1990;15(2):123-35.
92. Wittchen HU, Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry. 1999;60(Suppl 7):29-36 (discussion 7-8).
93. Gale CK. The treatment of generalised anxiety disorder: a systematic review. Panminerva Med. 2002;44(4):283-6.
94. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-95.
95. Hertzberg MA, Feldman ME, Beckham JC, Davidson JR. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996;16(4):294-8.
96. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128-31.
97. Mavissakalian M, Perel J, Bowler K, Dealy R. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144(6):785-7.
98. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986;47(12):580-6.
99. Milton S, Hershey Medical Center. Efficacy of trazodone vs. cognitive behavioral therapy in patients with chronic insomnia associated with objective short sleep duration [ClinicalTrials.gov identifier NCT01348542]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 5 June 2012.
100. Zavesicka L, Brunovsky M, Horacek J, et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett. 2008;29(6):895-901.
101. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5(1):15-20.
102. Yamadera H, Suzuki H, Nakamura S, Endo S. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci. 1999;53(2):189-91.
103. Mouret J, Lemoine P, Minuit MP, et al. Effects of trazodone on the sleep of depressed subjects: a polygraphic study. Psychopharmacology. 1988;95(Suppl):S37-43.
104. Parrino L, Spaggiari MC, Boselli M, et al. Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. Psychopharmacology. 1994;116(4):389-95.
105. van Bemmel AL, Havermans RG, van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology. 1992;107(4):569-74.
106. Ware JC, Pittard JT. Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry. 1990;51(Suppl):18-22.
107. Data on file, Angelini (2012).